All filters
Slidesets
Impact on: Adherence/tolerability - Ian McGowan, MB, ChB, DPhil, MD, FRCP
Presented at:
European HIV Clinical Forum 2016
Slidesets
Impact on: Virology/Resistance - Daniel Kuritzkes, MD
Presented at:
European HIV Clinical Forum 2016
Slidesets
A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined with Tenofovir/Emtricitabine or Abacavir/Lamivudine as a Switch Strategy for HIV-1 Pos. ART-exp. Patients with Stable Viral Suppression- Alberto Borghetti
Presented at:
European HIV Clinical Forum 2016
Slidesets
Impact on: Pharmacology – penetration to sanctuary sites and drug-drug interactions - Courtney Fletcher, PharmD
Presented at:
European HIV Clinical Forum 2016
Slidesets
Virological failure even at low levels of viremia can be associated to integrase strand-transfer inhibitors resistance in HIV-1 infected patients - Benet Garrabé
Presented at:
European HIV Clinical Forum 2016
Slidesets
French National survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS AC11 virology network) - Vincent Calvez
Presented at:
European HIV Clinical Forum 2016
Slidesets
An Italian case of transmitted integrase inhibitor resistance in a drug-naïve patient: a refined analysis by ultra-deep-454 pyrosequencing - Ada Bertoli
Presented at:
European HIV Clinical Forum 2016
Slidesets
Clinical Case Presentations – How to manage drug - drug interactions - the practice - Anna Maria Geretti, MD, PhD, FRCPath
Presented at:
European HIV Clinical Forum 2016
Slidesets
Clinical Utility of Integrase Inhibitors during pregnancy - Saye Khoo, MD, PhD
Presented at:
European HIV Clinical Forum 2016
Slidesets
Virological response of HIV-infected-patients virologically-suppressed switching to a DTG-based regimen in an observational cohort based on the genotypic susceptibility score - Diane Descamps
Presented at:
European HIV Clinical Forum 2016
Slidesets
Lamivudine plus either Atazanavir/ritonavir, Darunavir/ritonavir or Dolutegravir as switch strategies in HIV-positive, virologically-suppressed patients: a comparison - Alberto Borghetti
Presented at:
European HIV Clinical Forum 2016
Slidesets
Switching from combination antiretroviral therapy (cART) to dolutegravir (DTG) monotherapy in virologically suppressed HIV-1 infected adults: a randomized multicenter, non-inferiority clinical trial (DOMONO) - Ingeborg Wijting
Presented at:
European HIV Clinical Forum 2016
Slidesets
Induction-Maintenance ARV Therapy: Why, Who, When and How? - Pedro Cahn, MD, PhD
Presented at:
European HIV Clinical Forum 2016
Slidesets
Clinical Case Presentations - Experience with Induction-Maintenance Therapy in real life settings - José Arribas, MD
Presented at:
European HIV Clinical Forum 2016
Slidesets
Maintenance Therapy with Dolutegravir/Rilpivirin is efficient and well tolerated in a real-life setting - Katharina Grabmeijer Pfistershammer
Presented at:
European HIV Clinical Forum 2016
Slidesets
How to manage drug - drug interactions - the theory - Giovanni Di Perri, MD, PhD
Presented at:
European HIV Clinical Forum 2016